Arcturus Therapeutics Holdings Inc.
ARCTHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeArcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Valued at $449.7M, ARCT is a small-cap name in its sector. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Market Cap
$449.7M
Beta
2.48
P/E (TTM)
—
P/E (Fwd)
-4.38
EPS (TTM)
$-3.33
EPS (Fwd)
$-3.61
ROE
-46.3%
ROA
-24.0%
Cash
$191.5M
Total Debt
$22.9M
Free CF
$19.3M
52W Change
-11.8%
Annual Financials
Cash vs Debt
Where ARCT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ARCT finished 110.83% above its 150-day moving average ($7.94) and 118.25% above its 200-day moving average ($7.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARCT overbought or oversold?
At the September 3, 2026 close, ARCT's RSI(14) was 87.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $191.5M in cash and $22.9M in debt, ARCT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $19.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -46.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $205.8M (2022) to $67.2M (2025), a 67% decline worth watching.
With a beta above 1.5, ARCT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ARCT has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing ARCT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.